Floatz Rating
BB65/100
Confidence
Indicative
Sponsor
St. Jude Children's Research Hospital
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
60High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05292664CT.gov Venetoclax Basket Trial for High Risk Hematologic Malignancies | — | Recruiting | — | — | — |
NCT05476770CT.gov Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies | — | Recruiting | — | — | — |
NCT03792256CT.gov Palbociclib in Combination With Chemotherapy in Treating Children With Relapsed Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LL) | — | Completed | — | — | — |
NCT03817320CT.gov PO Ixazomib in Combination With Chemotherapy for Childhood Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma | — | Active Not Recruiting | — | — | — |
NCT01614197CT.gov A Trial of Temsirolimus With Etoposide and Cyclophosphamide in Children With Relapsed Acute Lymphoblastic Leukemia and Non-Hodgkins Lymphoma | — | Completed | — | — | — |
NCT02535806CT.gov Four Drug Reinduction With Bortezomib for Relapsed or Refractory ALL or LL in Children and Young Adults | — | Terminated | — | — | — |
NCT02043587CT.gov Chemotherapy With Liposomal Cytarabine CNS Prophylaxis for Adult Acute Lymphoblastic Leukemia & Lymphoblastic Lymphoma | — | Terminated | — | — | — |
NCT01700946CT.gov Therapy for Pediatric Relapsed or Refractory Precursor B-Cell Acute Lymphoblastic Leukemia and Lymphoma | — | Completed | — | — | — |
NCT01451515CT.gov NHL16: Study For Newly Diagnosed Patients With Acute Lymphoblastic Lymphoma | — | Completed | — | — | — |
NCT00873093CT.gov Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma | — | Completed | — | — | — |
Show 1 more trialShow fewer
NCT00002970CT.gov 506U78 in Treating Patients With Refractory Hematologic Cancer | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Lymphoblastic Lymphoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Hydrocortisone (this asset) | St. Jude Children's Research Hospital | Approved | BB · 65 |
| Rituximab | University of Washington | P4 | BBB |
| Cladribine | Fifth Affiliated Hospital, Sun Yat-Sen University | P4 | BBB |
| Etoposide | University of Washington | P4 | BBB |
| Mercaptopurine Anhydrous | City of Hope Medical Center | P4 | BBB |
| Pegaspargase | Chongqing Peg-Bio Biopharm Co., Ltd. | P4 | BBB |
| Vindesine | University Hospital Muenster | P4 | BBB |
| Cediranib | National Cancer Institute (NCI) | P2 | BB |
| Adriamycin | University of Washington | P4 | BB |
+42 more in the Lymphoblastic Lymphoma cohort
Other indications for Hydrocortisone
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Congenital Adrenal Hyperplasia | — | P4 | A · 81 |
| Childhood Acute Lymphoblastic Leukemia | — | P3 | BB · 68 |
| Adrenocortical Insufficiency | — | P3 | BB · 68 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Hydrocortisone in Lymphoblastic Lymphoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/hydrocortisone-lymphoblastic-lymphoma-14996
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →